Skip to main content Back to Top


Fluorescein Sodium and Proparacaine Hydrochloride Ophthalmic Solution

Products Affected - Description

    • Flucaine ophthalmic solution, OCuSOFT, 0.25%/0.5%, 5 mL bottle, 1 count, NDC 54799-0507-21
    • Fluorescein sodium/proparacaine hydrochloride ophthalmic solution, Altaire, 0.25%/0.5%, 5 mL bottle, 1 count, NDC 59390-0205-05

Reason for the Shortage

    • Altaire has recalled several medications due concerns over lack of sterility assurance. More information can be found at:

Available Products

    • There are no presentations available

Estimated Resupply Dates

    • Altaire has fluorescein/proparacaine 5 mL bottles on back order and the company cannot estimate a release date.
    • OCuSOFT has Flucaine 5 mL bottles on back order and the company cannot estimate a release date.


Updated September 30, 2019 by Megan Dryer, PharmD. Created July 26, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins